Cassava Sciences Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while ZIM Integrated Shipping Services Ltd trades at $25.24 (market cap $2.96B). The key difference: ZIM Integrated Shipping Services Ltd is far larger — about 62× Cassava Sciences Inc's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | ZIM | |
|---|---|---|
Market Cap | $47.75M | $2.96B |
Sector | Health | Industrials |
52-Week High | $4.64 | $29.27 |
52-Week Low | $0.87 | $12.44 |
Enterprise Value | -$34.93M | $6.81B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
ZIM trades at $25.27, up 0.24% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net income of $479.20 million in 2025, but profitability is expected to decline sharply in 2026. Recent news highlights uncertainty around a potential merger with Hapag-Lloyd and pressure from lower freight rates.
The outlook is cautious, with analysts evenly split between hold and sell ratings and a consensus price target of $16.75, well below the current price. Key risks include regulatory hurdles for the merger, volatile shipping rates, and declining earnings. Upside depends on successful deal execution or improved operational performance.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →